We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$227M
AUM Growth
+$19.5M
Cap. Flow
+$4.57M
Cap. Flow %
2.01%
Top 10 Hldgs %
68.95%
Holding
44
New
16
Increased
2
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$15.7M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$7.53M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$7.5M
4
STML
Stemline Therapeutics, Inc.
STML
+$7.27M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$6.98M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$14.9M
2
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$10.6M
3
ELGX
Endologix Inc
ELGX
+$9.94M
4
ARWR icon
Arrowhead Research
ARWR
+$8.32M
5
TOVX icon
Theriva Biologics
TOVX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 48.68%
2 Technology 25.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCM
26
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.16M 0.51%
5,000
– –
APYX icon
27
Apyx Medical
APYX
$173M
$1.15M 0.5%
+480,000
New +$1.6M
FRTX
28
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$800K 0.35%
269
-403
-60% -$1.29M
STRM
29
DELISTED
Streamline Health Solutions
STRM
$538K 0.24%
10,107
– –
VCYT icon
30
Veracyte
VCYT
$3.7B
$497K 0.22%
68,158
-486,268
-88% -$3.98M
ATHX
31
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$288K 0.13%
+4,000
New +$242K
OSIR
32
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$214K 0.09%
+12,165
New +$204K
LITS
33
Lite Strategy Inc
LITS
$32.8M
$94K 0.04%
2,613
-5,270
-67% -$472K
AGEN
34
Agenus
AGEN
$312M
– –
-46,889
Closed -$3.65M
ARWR icon
35
Arrowhead Research
ARWR
$11.9B
– –
-1,126,835
Closed -$8.32M
EXEL icon
36
Exelixis
EXEL
$13.3B
– –
-2,233,711
Closed -$3.22M
NBIX icon
37
PUT
Neurocrine Biosciences
NBIX
$16.8B
– –
-46,200
Closed -$1.03M
PLX icon
38
Protalix BioTherapeutics
PLX
$191M
– –
-21,322
Closed -$392K
TOVX icon
39
Theriva Biologics
TOVX
$9.64M
– –
-457
Closed -$5.84M
TRAW icon
40
Traws Pharma
TRAW
$6.85M
– –
-10
Closed -$1.82M
INFI
41
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-625,000
Closed -$10.6M
ELGX
42
DELISTED
Endologix Inc
ELGX
– –
-65,000
Closed -$9.94M
ANTH
43
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-31,250
Closed -$395K
ZGNX
44
DELISTED
Zogenix, Inc.
ZGNX
– –
-45,938
Closed -$503K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2015 Portfolio in Review

As of Q1 2015, Great Point Partners held 44 positions worth $227M, up 9.4% from $208M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Great Point Partners's Q1 2015 filing shows 16 new, 2 increased, 10 reduced and 11 closed positions. Its largest new stake was Vanda Pharmaceuticals: 1,388,599 shares worth $12.9M. The largest sale was HYPERION THERAPEUTICS INC COM STK (DE), an estimated $14.9M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 52% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q1 2015 buy was Vanda Pharmaceuticals: 1,388,599 shares worth $12.9M.
  • Great Point Partners added most to Adamas Pharmaceuticals in Q1 2015, an estimated $7.5M increase.
  • Great Point Partners's biggest Q1 2015 reduction was HYPERION THERAPEUTICS INC COM STK (DE), cutting an estimated $14.9M.
  • Great Point Partners fully exited Infinity Pharmaceuticals, Inc. in Q1 2015, selling an estimated $10.6M.
  • Great Point Partners's ten largest holdings make up 69% of its $227M portfolio in Q1 2015.
  • Great Point Partners opened 16 new positions and closed 11 in Q1 2015.
  • Great Point Partners's portfolio value rose 9.4% quarter-over-quarter to $227M.

Based on Great Point Partners's 13F filing for Q1 2015, filed 15 May 2015.